Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Blood

Volumn 124, Issue 1, 2014, Pages 13-23

  Placke, Theresa ^a,b   Faber, Katrin ^c   Nonami, Atsushi ^d   Putwain, Sarah L ^e   Salih, Helmut R ^b,f   Heidel, Florian H ^g   Krämer, Alwin ^b,h   Root, David E ⁱ   Barbie, David A ^d,i   Krivtsov, Andrei V ^j   Armstrong, Scott A ^j   Hahn, William C ^d,i   Huntly, Brian J ^e   Sykes, Stephen M ^k   Milsom, Michael D ^a   Scholl, Claudia ^c   Fröhling, Stefan ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Department of Molecular Biology of Cell I   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g OTTO VON GUERICKE UNIVERSITY   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k FOX CHASE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CYCLIN DEPENDENT KINASE 6; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; MESSENGER RNA; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR PU 1; ONCOPROTEIN; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOME REARRANGEMENT; COLONY FORMATION; CONTROLLED STUDY; GENE REPRESSION; GENOTYPE; GROWTH INHIBITION; HUMAN; HUMAN TISSUE; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; C57BL MOUSE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC TRANSDUCTION; GENETICS; IMMUNOBLOTTING; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 6; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOBLOTTING; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

EID: 84903954701     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-558114     Document Type: Article

References (59)

1. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
2. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
3. Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165-2176.
4. Krauter J, Wagner K, Schäfer I, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient databased meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2009; 27(18):3000-3006.
5. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818-822. (Pubitemid 44258912)
6. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10(4):257-268. (Pubitemid 44512188)
7. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984-993.
8. Mohan M, Herz H-M, Takahashi Y-H, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24(6):574-589.
9. Biswas D, Milne TA, Basrur V, et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci USA. 2011; 108(38):15751-15756.
10. Tan J, Jones M, Koseki H, et al. CBX8, a polycomb group protein, is essential for MLLAF9- induced leukemogenesis. Cancer Cell. 2011; 20(5):563-575.
11. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110(13):4445-4454. (Pubitemid 351377811)
12. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529-533.
13. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370): 524-528.
14. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell. 2012;21(4):473-487.
15. Kuo H-P, Wang Z, Lee D-F, et al. Epigenetic roles of MLL oncoproteins are dependent on NF-kB. Cancer Cell. 2013;24(4):423-437.
16. Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007;26(47):6766-6776. (Pubitemid 47585101)
17. Gröschel S, Schlenk RF, Engelmann J, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German- Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol. 2013;31(1): 95-103.
18. Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8(3): 277-284.
19. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
20. Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature. 2008;455(7217): 1205-1209.
21. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
22. Yeung J, Esposito MT, Gandillet A, et al. b-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell. 2010;18(6):606-618.
23. Boehm JS, Hahn WC. Towards systematic functional characterization of cancer genomes. Nat Rev Genet. 2011;12(7):487-498.
24. Bernards R. A missing link in genotype-directed cancer therapy. Cell. 2012;151(3):465-468.
25. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009;137(5):821-834.
26. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108- 112.
27. Weber K, Thomaschewski M, Warlich M, et al. RGB marking facilitates multicolor clonal cell tracking. Nat Med. 2011;17(4):504-509.
28. Faber K, Bullinger L, Ragu C, et al. CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARg signaling. J Clin Invest. 2013; 123(1):299-314.
29. Kutner RH, Zhang XY, Reiser J. Production, concentration and titration of pseudotyped HIV-1- based lentiviral vectors. Nat Protoc. 2009;4(4): 495-505.
30. Bernt KM, Zhu N, Sinha AU, et al. MLLrearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20(1):66-78.
31. Dolgin E. Cancer's true breakthroughs. Nat Med. 2013;19(6):660-663.
32. Armstrong SA, Golub TR, Korsmeyer SJ. MLL-rearranged leukemias: insights from gene expression profiling. Semin Hematol. 2003;40(4): 268-273. (Pubitemid 37296776)
33. Kumar AR, Li Q, Hudson WA, et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood. 2009; 113(8):1756-1758.
34. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009;113(11): 2375-2385.
35. Kroon EE, Krosl JJ, Thorsteinsdottir UU, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17(13):3714-3725. (Pubitemid 28327389)
36. Wang QF, Wu G, Mi S, et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood. 2011;117(25):6895-6905.
37. Guenther MG, Lawton LN, Rozovskaia T, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22(24):3403-3408.
38. Jares PP, Colomer DD, Campo EE. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
39. Canavese MM, Santo LL, Raje NN. Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther. 2012; 13(7):451-457.
40. Whiteway SL, Harris PS, Venkataraman S, et al. Inhibition of cyclin-dependent kinase 6 suppresses cell proliferation and enhances radiation sensitivity in medulloblastoma cells. J Neurooncol. 2013;111(2):113-121.
41. Wiedemeyer WRW, Dunn IFI, Quayle SNS, et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA. 2010;107(25): 11501-11506.
42. Chilosi M, Doglioni C, Yan Z, et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol. 1998;152(1): 209-217. (Pubitemid 28028061)
43. Hu MG, Deshpande A, Enos M, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 2009;69(3):810-818.
44. Corcoran MM, Mould SJ, Orchard JA, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18(46):6271-6277.
45. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
46. Wölfel TT, Hauer MM, Schneider JJ, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281-1284.
47. Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012; 18(10):1503-1510.
48. Puyol M, Martín A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010;18(1): 63-73.
49. Fujimoto TT, Anderson KK, Jacobsen SEWS, Nishikawa S-IS, Nerlov CC. Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA binding and Runx1-C/EBPalpha interaction. EMBO J. 2007;26(9):2361-2370.
50. Handschick K, Beuerlein K, Jurida L, et al. Cyclindependent kinase 6 is a chromatin-bound cofactor for NF-kB-dependent gene expression. Mol Cell. 2014;53(2):193-208.
51. Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167-181.
52. Malumbres MM, Sotillo RR, Santamaría DD, et al. Mammalian cells cycle without the D-type cyclindependent kinases Cdk4 and Cdk6. Cell. 2004; 118(4):493-504.
53. Hu MGM, Deshpande AA, Schlichting NN, et al. CDK6 kinase activity is required for thymocyte development. Blood. 2011;117(23):6120-6131.
54. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013;31(16):2024-2028.
55. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597-4607.
56. Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclindependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012; 18(2):568-576.
57. Mi J-Q, Li J-M, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012;26(8):1743-1751.
58. Jo SYS, Granowicz EME, Maillard II, Thomas DD, Hess JLJ. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood. 2011;117(18): 4759-4768.
59. Nguyen ATA, He JJ, Taranova OO, Zhang YY. Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res. 2011;21(9): 1370-1373.